• In recent days, AbbVie has reported new hematology data at the EHA 2026 Congress, advanced its CLL and migraine portfolios in Europe, and managed smaller regulatory items such as an ophthalmic recall and FDA withdrawal of certain no-longer-marketed generics.
• Together, these updates highlight how AbbVie is leaning on hematology and neuroscience assets, including venetoclax combinations and AQUIPTA, to broaden revenue sources beyond its legacy blockbusters.
• Next, we will examine how AbbVie’s expanded CLL and migraine indications at EHA and in Europe may reshape its investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

AbbVie Investment Narrative Recap

To own AbbVie today, you need to believe its newer immunology, hematology and neuroscience franchises can collectively offset patent and pricing pressure on legacy cash cows. The latest CLL and migraine updates mostly reinforce, rather than change, the near term focus on pipeline execution as a key catalyst, while the biggest risk remains pricing and policy pressure on high value therapies.

The European Commission’s expanded label for VENCLYXTO in first line CLL, using fixed duration combinations with acalabrutinib or ibrutinib, lines up closely with AbbVie’s CLL14 and AMPLIFY data at EHA. Together, these moves help clarify how hematology, alongside AQUIPTA’s growing migraine footprint, fits into the effort to deepen and diversify revenue beyond Humira, Skyrizi and Rinvoq.

Yet, despite this progress, investors should be aware of how concentrated AbbVie still is in a few high priced drugs…

AbbVie's narrative projects $79.1 billion revenue and $23.2 billion earnings by 2029. This requires 8.0% yearly revenue growth and a $19.6 billion earnings increase from $3.6 billion today.

Uncover how AbbVie's forecasts yield a $253.55 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for AbbVie span roughly US$253 to US$441, showing how far apart individual views can be. Some community members focus on hematology and neuroscience catalysts while others are more cautious about patent and pricing risks, so it is worth comparing several of these perspectives before forming your own view.

Explore 3 other fair value estimates on AbbVie - why the stock might be worth just $253.55!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.